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Abstract
Frontotemporal dementia (FTD) is the second most prevalent form of pre-senile dementia after Alzheimer’s disease.
Amyotrophic lateral sclerosis (ALS) can overlap genetically, pathologically and clinically with FTD indicating the two
conditions are ends of a spectrum and may share common pathological mechanisms. FTD–ALS causing mutations are
known to be involved in endosomal trafficking and RNA regulation. Using an unbiased genome-wide genetic screen to
identify mutations affecting an FTD–ALS-related phenotype in Drosophila caused by CHMP2BIntron5 expression, we have
uncovered repressors of retrovirus (RV) activity as modifiers of CHMP2BIntron5 toxicity. We report that neuronal expression of
CHMP2BIntron5 causes an increase in the activity of the endogenous Drosophila RV, gypsy, in the nervous system. Genetically
blocking Drosophila gypsy activation and pharmacologically inhibiting viral reverse transcriptase activity prevents
degenerative phenotypes observed in fly and rat neurons. These findings directly link endosomal dysfunction to RV
de-repression in an FTD–ALS model without TDP-43 pathology. These observations may contribute an understanding to
previous discoveries of RV activation in ALS affected patients.
Introduction
Frontotemporal dementia (FTD) is the second most common
form of dementia in individuals under 60 years of age (1). FTD
is characterized by atrophy of the frontal and temporal lobes.
Within these brain regions, von Economo neurons are first
affected triggering behavioral changes and cognitive impair-
ment (2). FTD can co-occur with amyotrophic lateral sclerosis
(ALS) and both conditions share clinical, neuropathological and
genetic features, suggesting they may constitute two ends of a
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disease continuum (3–5) with approximately 15% of FTD patients
developing ALS and vice versa (6).
Mutations in chromatin-modifying protein 2B (CHMP2B) have
been found to cause rare cases of FTD (7,8), but have also been
identified in someALS cases (9–11) and in FTD–ALS (12). CHMP2B
encodes a core component of the endosomal sorting complex
required for transport-III (ESCRT-III) involved in transport of
ubiquitinated proteins from the cell membrane to the lyso-
some (13). The pathological FTD-causing CHMP2BIntron5 mutation
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endosomal trafficking resulting in autophagosome accumula-
tion leading to neurodegeneration. The CHMP2BIntron5 mutation
causes a form of FTDwith no apparent TARDNA-binding protein
43 (TDP-43), FUS or tau proteinopathy (14). Previous studies
have established a Drosophila model of CHMP2BIntron5 (15), which
has facilitated the unbiased screening for genetic modifiers
of CHMP2BIntron5 toxicity identifying innate immune activation,
autophagosomal and endosomal dysfunction (15–18). Here, we
describe the identification of retrovirus (RV) reactivation as a
potent modifier of the CHMP2BIntron5 phenotype.
Endogenous RVs are present in most eukaryotic genomes,
accumulating in heterochromatic regions (19). They can act as
genetically mobile elements that can replicate and move within
the genome negatively affecting host health. RVs contain three
open reading frames (ORFs) consisting of group-specific antigen
(GAG), polymerase (POL) and envelope (ENV) components that upon
activation, encode the capsid, reverse transcriptase and ENV
protein of the virus, respectively. RVs can be initially repressed
via cellular antiviral mechanisms and later domesticated and
endogenizedwithin the genome over time,with gain-and-loss of
ORFs and ORFs evolving to generate novel proteins (20). In order
to prevent RV activation, transposition and infection, eukaryotic
cells have developed potent RV suppression mechanisms: small
RNA molecules associated with the piwi protein termed piRNAs
(21,22), which are known to act in the germline, and siRNAs that
have a somatic role (23). An increase in RV expression has been
documented in FTD–ALS postmortem tissue (24–26) suggesting
that the RV silencing machinery might be disrupted potentially
through TDP-43 dysfunction (27–29). An increase in the reverse
transcriptase activity of human endogenous RV (hERV)-K has
been documented in ALS patient serum and cerebrospinal fluid
but the link between ALS pathology and RV abundance has yet to
be fully identified (30). Neuronal expression of the hERV-K ENV
protein inmice induced anALS-like conditionwith loss of upper-
and lower-motor neurons (26). These findings have been fol-
lowed by clinical studies using nucleoside reverse transcriptase
inhibitors as potential therapeutic treatments for ALS (31). Why
RVs might be de-repressed in ALS tissue in some patients and if
they may contribute to pathology has yet to be fully elucidated.
We have identified mutations in genes functioning in RV
repression as dominant genetic enhancers and suppressors of
CHMP2BIntron5 expression in Drosophila eye. Mutations, knock-
down or overexpression of the RV repression component genes
encoding Brother-of-Yb (BoYb), piwi, Sister-of-Yb (SoYb) and Vreteno
(Vret) are seen to enhance and suppress an innate immune acti-
vation eye phenotype associated with CHMP2BIntron5 expression
(15). Quantification of RV insertions in genomic DNA from flies
neuronally expressing CHMP2BIntron5 shows an elevation of gypsy
elements inserted in the genomewith a concomitant increase in
expression of the gypsy ENV protein. We show that knockdown
of ENV protein via gypsy-RNAi in the presence of CHMP2BIntron5
alleviates photoreceptor cell death. Finally, we demonstrate that
the addition of reverse transcriptase inhibitors in primarymam-
malian neurons transfected with CHMP2BIntron5 significantly res-
cues the neuronal dendritic retraction caused by CHMP2BIntron5
expression.
Results
A genetic screen in Drosophila identifies RV repression
components as modifiers of CHMP2BIntron5 toxicity
The CHMP2BIntron5 mutation was identified in a large Danish
family causing FTD on chromosome 3 [FTD-3; (7)]. In this study,
we overexpressed this human mutant form in the Drosophila
eye using the glass multimer reporter (GMR) promoter. This
induces a rough eye with melanotic deposits [Fig. 1A; (15)].
The melanotic spots represent an innate immune activation
and we principally quantify the level of melanization in our
screen as a measure of FTD–ALS-related neuronal death and
dysfunction (15). This model has identified several modifiers of
CHMP2BIntron5 (15–18). From a genome-wide unbiased screen for
enhancers and suppressors of this phenotype, we identified a
heterozygous mutation in BoYb as a dominant genetic enhancer
of CHMP2BIntron5 related toxicity (Fig. 1A and B). BoYb knockdown
via RNAi potentiated the CHMP2BIntron5 melanization phenotype
whereas overexpression reduced the melanization of the eye
caused by CHMP2BIntron5 (Fig. 1A). BoYb is a component of the
Yb-nuage piRNA regulatory machinery (32). To confirm and
extend this data in vivo, a targeted screen using mutations
and transgenes for other components of the RV repression
machinery was performed to test for dominant modification of
the CHMP2BIntron5 eye expression phenotype. Novel enhancers
and suppressors identified included piwi, SoYb and Vret
[Fig. 1A–D; (33)]. Enhancement of melanization by piwi was
consistent for two additional identified piwi mutant alleles
(Fig. 1C and D). Each of these are core components of the
Drosophila Yb-nuage complex involved in RV repression (34).
In control flies driving GMR-Gal4, these crosses had minimal
effects on eye degeneration (Fig. 1A).
Neuronal CHMP2BIntron5 expression leads to gypsy
activation
Having identified a genetic interaction between piRNA reg-
ulatory machinery and CHMP2BIntron5 expression in the fly
eye, the molecular pathways involved in RV upregulation in
the Drosophila FTD–ALS model expressing CHMP2BIntron5 were
investigated. Levels of several RV genomic elements were
examined by quantitative polymerase chain reaction (qPCR) in
heads of flies expressing GMR>CHMP2BIntron5. Only insertions
of the endogenous Drosophila RVs gypsy, gypsy-6 and tirant
were observed to be significantly upregulated in the genome
of GMR >CHMP2BIntron5 fly heads, with gypsy being the most
strongly increased in abundance compared with wild-type and
ago2 mutants, AGO2454/321 (Supplementary Material, Fig. S1A),
a positive control known to regulate RVs (35,36). Individual RV
elements can degenerate and lose ORFs from the RV element,
but still be mobilized in a non-autonomous manner by intact
RVs. To examine the abundance of degenerate gypsy elements
in the presence of CHMP2BIntron5, we quantified the gypsy-
genome components GAG, POL, ENV and LTR copy levels in
the CHMP2BIntron5 expressing genome (Supplementary Material,
Fig. S1B). A significant increase was observed only for the
ENV (Fig. 1A and Supplementary Material, Fig. S1B) and LTR
(SupplementaryMaterial, Fig. S1B) sequences in theCHMP2BIntron5
expression background compared with the wild-type indicating
a mobilization of a degenerate gypsy element containing
ENV.
Given the increase of gypsy-ENV sequence in CHMP2BIntron5
flies (Fig. 2A), ENV protein levels in CHMP2BIntron5 expressing
tissue were then examined. Immunoblotting using an anti-
gypsy-ENV antibody (37) confirmed ENV to be present in
CHMP2BIntron5 expressing and AGO2454/321 mutant heads in
comparison to the wild-type heads (Fig. 2B), indicating a sig-
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Figure 1. Manipulating levels of BoYb, piwi, SoYb and Vret perturbs melanization in the CHMP2BIntron5 expressing Drosophila eye. Representative eye of GMR-
Gal4:UAS-CHMP2BIntron5/+ (GMR>CHMP2BIntron5) (A). BoYb knockdown via RNAi showed an enhancement on the eye blackening, whereas overexpression rescued
the melanization caused by CHMP2BIntron5 expression. Reduction of piwi levels via Piwi-RNAi strongly increased the CHMP2BIntron5 eye melanization. A single copy of
SoYb-RNAi and Vret-RNAi reduced the toxicity on the eye caused by CHMP2BIntron5 , whereas SoYb and Vret overexpression enhanced the CHMP2BIntron5 melanization
phenotype. (B) Quantification of the eye melanization severity from A genotypes (n=100). (C) A single copy of the mutant alleles piwi1–2 enhanced the toxicity of the
eye melanization caused by CHMP2BIntron5 expression. (D) Quantification of the eye melanization severity from C genotypes (n=100).
Gypsy mobilization is observed in vivo in CHMP2BIntron5
expressing neurons
To test whether gypsy is an active RV transposing physically in
the presence of CHMP2BIntron5, we employed a reporter system
based on RV integration into a genomic RV landing hotspot,
known as ovo (38). We used a reporter system termed gypsy-
TRAP to detect de novo insertions of gypsy [Fig. 3A; (28)]. In
this system, a promoter-Gal4 construct is used to drive GFP
in a tissue of interest, here OK6-Gal4, which expresses in
motor neurons. In the same fly, Gal80 is expressed under
the control of an α-tubulin-promoter repressing Gal4 in all
tissues. Between the α-tubulin-promoter and the Gal80 element
there is a section of the ovo promoter, a genomic hotspot
for gypsy insertion events (37). If gypsy elements jump into
the intervening hotspot, Gal80 expression is reduced and
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Figure 2. Increased gypsy-ENV expression is detected in pan-neuronally expressing CHMP2BIntron5 Drosophila. (A) Fold change in expression of gypsy-ENV measured
in wild-type (+), GMR-Gal4:UAS-CHMP2BIntron5 (GMR>CHMP2BIntron5) and AGO2454/231 mutant fly heads by qPCR. Transcript levels are normalized to Rpl32 and fold-
change values are relative to wild-type flies. Error bars indicate standard error (Kruskal–Wallis test, ∗∗∗∗P< 0.0001). (B) Immunoblot showing ENV levels in wild-type,
GMR>CHMP2BIntron5 and AGO2454/321 adult heads.
(Fig. 3A and B). To allow both CHMP2BIntron5 and CHMP2BWildtype
expression in combination with the gypsy-TRAP system, a Gal4
independent expression system was employed. To achieve this,
the LexA/LexAop system (39) was used to express CHMP2BWildtype
and CHMP2BIntron5. To ensure genetic consistency for the
initial number of genomic gypsy insertions prior to CHMP2B
induced activation, both constructs were genomically site
landed to ensure identical genomic backgrounds and equivalent
expression levels of both CHMP2BWildtype and CHMP2BIntron5
proteins. Transposition was assayed in motor neurons of pan-
neuronal expression of CHMP2BWildtype or CHMP2BIntron5 via
nSyb-LexA (Fig. 3B). In the presence of Gal80 and absence
of CHMP2BIntron5 expression, GFP is silenced and few motor
neurons are labeled.WhenCHMP2BIntron5 is neuronally expressed,
we observed GFP expression in multiple single motor neurons
(Fig. 3B and C). In the presence of CHMP2BIntron5, the gypsy-
TRAP highlights a significant increase in gypsy mobilization
in CHMP2BIntron5 expressing cells compared with CHMP2BWildtype
(Fig. 3B and C). Togetherwith the findings described above, these
results demonstrate that gypsy activity is higher in CHMP2BIntron5
expressing Drosophila neurons.
Having identified an upregulation of gypsy-ENV and gypsy-
mediated transposition events in CHMP2BIntron5 expressing
neurons, we then asked whether it was possible to rescue
the melanized eye phenotype caused by GMR>CHMP2BIntron5
via gypsy downregulation (Fig. 3D and E). Three different RNAi
constructs targeting gypsywere tested for their ability to reverse
melanization in fly eyes expressing CHMP2BIntron5 (40). Reducing
gypsy via the three different RNAi constructs alleviated the
melanization phenotype in the fly eye caused by CHMP2BIntron5
expression (Fig. 3D and E).
Inhibition of reverse transcriptase rescues neuronal
aberrations caused by mammalian CHMP2BIntron5
expression
Having observed an amelioration of the melanized eye phe-
notype in Drosophila when gypsy was inhibited, we asked
whether similar effects could be recapitulated in mammalian
models. Neurons transfected with CHMP2BIntron5 develop a
significant retraction of the dendritic arbor when compared
with CHMP2BWildtype expressing controls [Fig. 4; (18)]. Stavudine
(D4T) and lamivudine (3TC) are nucleoside analogue reverse
transcriptase inhibitors that are widely used to inhibit human
immunodeficiency virus replication in patients and are well
tolerated as an anti-retroviral therapy (41). Primary neurons
transfected with CHMP2BIntron5 showed a significant dendritic
collapse phenotype compared with neurons transfected with
CHMP2BWildtype. CHMP2BIntron5 expressing neurons develop a sig-
nificant reduction in the length of the longest neuronal process
(Fig. 4B, 40% reduction) and a reduction in total arbor size (Fig. 4C,
60% reduction) when compared with CHMP2BWIldtype expressing
controls. This reduced complexity of the dendritic arbor was
further analyzed using Sholl analysis,with a significant decrease
in the cumulative number of intersections observed compared
with wild-type controls (Fig. 4D). Administration of 10 μm of
D4T (Stavudine) (48 h; Fig. 4) was sufficient to rescue these
altered dendritic phenotypes. This observation was further
confirmed with the administration of 10 μm 3TC (Lamivudine)
(Supplementary Material, Fig. S2).
We observe that manipulation of cellular RV silencing
machinery rescues innate immune related melanization pheno-
types in the Drosophila eye caused by CHMP2BIntron5 expression.
Additionally inhibition of retroviral reverse transcriptase in
mammalian neurons expressing CHMP2BIntron5 rescues dendritic
collapse. Inhibition of gypsy via RNAi and administration of
retroviral reverse transcriptase inhibitors D4T or 3TC was able
to alleviate neurodegeneration-related phenotypes compared
with controls (Figs 3D and E, Fig. 4; Supplementary Material, Fig.
S2). Together, these data suggest that RV activity is increased
in our Drosophila model and confirm that suppression of RV
activation in both Drosophila and mammalian neurons reduces
neurotoxicity, indicating RV suppression would be an attractive
target for FTD–ALS treatment.
Discussion
Our observations usingDrosophila as amodel for the FTD-causing
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Figure 3. The gypsy-TRAP reporter confirms increased de novo insertion of gypsy in CHMP2BIntron5 expressing Drosophila brains. (A) Schematic of the gypsy-TRAP
mobilization assay. De-repressed gypsy jumps into the hotspot ovo binding site and disrupts Gal80, triggering GFP expression in motor neurons. Image created with
BioRender. (B) Pan neuronally driven (nSyb-LexA) CHMP2BIntron5 brains show increased GFP-positive cells compared with pan neuronally driven CHMP2BWildtype brains.
GFP-positive cells represent gypsy mobilization events, which are limited to the motor neurons because of the OK6-Gal4 driver. Scale bar, 10 μm. (C) Quantification
of GFP-labeled neurons observed in nSyb>CHMP2BWildtype and nSyb>CHMP2BIntron5 expressing Drosophila brains (t test, ∗P< 0.01). (D) Inhibition of gypsy via three
different gypsy-RNAi (1, 2 and 3) rescued the degenerative eye phenotype caused by GMR-Gal4:UAS-CHMP2BIntron5 (GMR>CHMP2BIntron5). (E) Quantification of the eye
phenotypes from (D) genotypes (n=100).
RV gypsy in CHMP2BIntron5 expressing Drosophila brains. Here,
the RNA-silencing machinery Yb components, including BoYb,
SoYb, Vret and piwi, were identified as dominant modifiers
of CHMP2BIntron5 toxicity. Recent reports have found levels of
RV encoded reverse transcriptase activity in serum and cere-
brospinal fluid of FTD–ALS patients (30,42–45). Other studies
have found in postmortem ALS tissue the presence of ENV,
encoded by hERV-K, a human RV akin to Drosophila-gypsy (26,46).
These findings have been replicated in a TDP-43 expressing
Drosophila model of FTD–ALS (28,47). In this investigation, gypsy,
gypsy-6 and tirant insertions were increased in the presence of
CHMP2BIntron5 among other RVs suggesting differential regula-
tion of RVs. We focused our study on the well characterized
RV gypsy. Here, a significant increase in gypsy-ENV transcript,
as well as an upregulation of the glycoprotein ENV, is found
in CHMP2BIntron5 expressing Drosophila heads. An increase in RV
transcripts identified through a transcriptome analysis from
C9orf72-affected patients has been previously observed (48). In
an in vitro study to confirm hERV-K-ENV pathogenicity, the hERV-
K-ENV ORF was transfected into human neuronal cells, which
induced a decrease in cell number (26). In the same study, a
transgenic mouse expressing hERV-K-ENV protein under a neu-
ronal promoterwas constructed and these animals developed an
evident motor neuron degeneration, DNA damage and cortical
thinning of the rostral part of themotor cortex (26). This suggests
that the activation of these elements may be conserved and
present among different FTD–ALS-causative mutations, though
not all patients showelevated levels of hERV-K.RV elements have
been characterized as TDP-43 targets at the DNA level (47) and an
increase in RV expression found in ALS patients correlates with
TDP-43 pathology (49). Although CHMP2BIntron5 patients do not
have apparent TDP-43 inclusions in the cytoplasm (12), manipu-
lation of functionally associated ESCRT proteins can cause TDP-
43 aggregation (50). We therefore cannot rule out a role for
compromised TDP-43 function in CHMP2BIntron5 associated RV
re-activation.
The suppression of RVs through reverse transcriptase
inhibitors can ameliorate neurological defects associated with
aging and FTD–ALS inDrosophilamodels (47,51). Here,we provide
evidence that gypsy knockdown alleviates neuronal defects
in our Drosophila model of FTD caused by the CHMP2BIntron5
mutation. In our rat primary neuron model of FTD caused
by CHMP2BIntron5 expression, reverse transcriptase inhibition
is proposed to block mRNA production from RV elements via
the inhibition of POL activity and the subsequent production
of further GAG, POL and ENV proteins. Using two clinically
well-characterized antiviral reverse transcriptase inhibitors,
stavudine (D4T) and lamivudine (3TC), we were able to prevent
the development of dendritic collapse in rat primary neurons
expressing CHMP2BIntron5 (Fig. 4; Supplementary Material, Fig.
S2). Preventing RV mobilization may help to limit neuronal
and/or glial cell death in FTD–ALS. Recent studies have pointed
to a role for TDP-43 in repressing RVs and retrotransposons
(RTs), which also act via reverse transcriptase POL activity,
both in human and Drosophila DNA (47,51–53). Around 50% of
FTD patients do not have TDP-43 misregulation while 97% of
ALS patients have TDP-43 aggregation (54,55), suggesting that
only TDP-43-positive patients would benefit from RV inhibition.
CHMP2BIntron5-affected patients are TDP-43-negative (7). In our
Drosophila model expressing CHMP2BIntron5, RV disruption may
be caused by other factors and not only by TDP-43 disturbance.
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Figure 4. The retroviral reverse transcriptase inhibitor Stavudine (D4T) rescues dendritic collapse inmammalian neurons expressing CHMP2BIntron5 . (A) Representative
micrographs of mature neurons expressing FLAG-tagged CHMP2BWildtype or CHMP2BIntron5 in the absence and presence of D4T (Stavudine). Scale bar, 50 μm. Longest
process length (B) and total arbor size (C) in CHMP2BIntron5 expressing neurons are significantly increased upon addition of D4T. (D) CHMP2BIntron5 presents a reduced
cumulative branch number partially rescued by D4T. (B–D) One-way ANOVA with Tukey’s post-hoc comparing CHMP2BIntron5 and without D4T (∗∗P<0.01, ∗∗∗P<0.001).
MATR3, TDP-43, TIA1, hnRNPA1 and TAF15, are found to bind
and regulate the RT LINE1 RNA elements (56). This suggests that
disruption of RBP function might dysregulate RV/RT repression.
Thus, CHMP2BIntron5-affected patients could also benefit from RV
inhibition, as our data suggests. Our work provides functional
evidence for a conserved mechanism between Drosophila
and mammalian models of FTD–ALS where RV inhibition
provides an amelioration of the neurodegenerative condition
via mechanisms that are yet to be discovered.
Materials and Methods
Fly stocks and maintenance
Flies were raised at 25◦C on standard yeast, sugar and agar
medium on a 12 h light:dark cycle. Unless otherwise stated,
Canton-S was used for control. The following Drosophila
lines were obtained from the Bloomington Stock Center,
Indiana: UAS-BoYb (BL#28446), UAS-BoYb-RNAi (BL#62432),
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UAS-SoYb (BL#26961), UAS-SoYb-RNAi (BL#36881), UAS-Vret
(BL#22204), UAS-Vret-RNAi (BL#38212), AGO2454 (BL#36522),
AGO2321 (BL#36511), glass multiple reporter GMR-Gal4 (BL#1104),
neuronal synaptobrevin (nSyb)-LexA (BL#52817), OK6-Gal4 (Cahir
O’Kane,University of Cambridge,UK),UAS-mCD8-GFP (BL#32186).
For the genetic screen, lines containing GMR-Gal4 and UAS-
CHMP2BIntron5 were recombined into the second chromosome
as described elsewhere (15). gypsy-TRAP transgenic flies were
a gift from Josh Dubnau (28). gypsy-RNAi transgenic flies were
obtained from Jeng Pin (40). For flies used in gDNA extraction
experiments, UAS-CHMP2BIntron5 and UAS-CHMP2BWildtype (15)
were maintained in the same w1118 background and crossed
to GMR-GAL4 to ensure identical genetic backgrounds.
Genetic interaction studies
To quantify the CHMP2BIntron5 eye phenotype, the classification
was divided into low, medium or high levels of melaniza-
tion. GMR-GAL4::UAS-CHMP2BIntron5 (GMR>CHMP2BIntron5) virgin
femaleswere crossed tomutant and transgenic stocks. Eyeswere
imaged using a camera (AxioCam Erc 5 s; Carl Zeiss, Germany)
on a dissecting scope (Stemi 2000-C; Carl Zeiss).
Generation of transgenic fly lines
To generate LexAop-CHMP2BWildtype and LexAop-CHMP2BIntron5
transgenic flies, the primers listed in Supplementary Material,
Table S1 were used to amplify CHMP2BIntron5 and CHMP2BWildtype
and cloned into a pJFRC19-13XLexAop2-IVS-myr::GFP vector
(57) (Addgene, USA, Cat No. 26224) via the BglII and Xba1
cloning sites. Constructs were then sequenced and inserted
into the Drosophila genome at the attP40 insertion site via
C31-mediated site-specific attP integration. Integration at
the attP40 site on the second chromosome was achieved by
microinjection into the stock: y,w,M(eGFP, vas-int, dmRFP)ZH-
2A; P{CaryP}attP40. Microinjections were carried out by the
Cambridge Microinjection Service (UK).
Immunohistochemistry
Drosophila immunohistochemistry was performed as described
elsewhere (17). Primary antibodies used were: mouse anti-
elav (DSHB 9F8A9, 1:50) and FluoTag®-X4 anti-GFP (NanoTag
Biotechnologies, Germany, 1:1000). Primary antibodies were
incubated with preparations overnight at 4◦C. The following
day, after washing with PBT they were incubated with the
appropriate secondary antibodies for 1 h at room temperature
before washing with PBT and mounting with Vectashield
Mounting Medium (Vector Labs, USA). Control larvae were
stained in the same solutions as experimental larvae. For rat
primary neuron immunohistochemistry, cells were fixed and
stained as previously described (58) using anti-FLAG (Sigma,
USA, M2 clone, 1:1000). Primary antibodies were incubated
overnight at 4◦C. Corresponding Alexafluor secondary antibod-
ies (Thermo Scientific, USA, 1:500) were incubated for 1 h at
room temperature before mounting with Fluoromount (Sigma).
Confocal microscopy and image analysis
For imaging Drosophila tissue, confocal images were acquired
using a ZEISS LSM 880 confocal microscope using a 20× or 40×
objectives using Zeiss filter sets for Alexa 488/561/633. Z-stack
images of larvae brains were obtained using 20× or 40× NA
oil objective. Images stacks were merged and processed using
Fiji. For imaging rat primary neurons, images were collected
on an inverted Zeiss microscope (880) with 20× Plan Neofluar
objectives using Zeiss filter sets for DAPI and Alexa 488/546.
Images were taken at an aspect ratio of 1024× 1024. Images of
neurons were traced using the NeuronJ plugin in ImageJ (1.6.0).
Individual traceswere saved, thresholded and Sholl analysis was
conducted using the Sholl plugin.
qPCR data analysis
gDNA was extracted using Puregene Core Kit A (Qiagen). SYBR®
green assays were used to perform the qPCR analysis on a
QuantStudio3 Real Time PCR System (Thermo Fisher Scientific,
USA). Samples were run in triplicate and normalized to rpl32
expression. Relative expression of genes was determined by
the 2−Ct method (59). Primers are listed in Supplementary
Material, Table S1.
Protein extraction and immunoblot
Fifty adult fly heads were homogenized in 30 μL of 2× Laemmli
loading buffer. After boiling, samples were run on a 4–20% Mini-
PROTEAN® TGXTM Precast Protein Gels (Biorad, USA) and trans-
ferred to PVDF membrane (Invitrogen, USA). Primary antibodies
used include: mouse anti-ENV (37), anti-ß-Actin (Proteintech,
USA, 60008–1-Ig, 7D2C10, 1:8000) and anti-ß-tubulin E7 (DSHB,
1:5000).
Culture of primary neurons
Timed-mated female Wistar rats (Charles River, UK) (RRID:-
RGD_737929) were maintained in accordance with the UK Ani-
mals (Scientific Procedures) Act (1986). Cortices were dissected
from postnatal day 1 (P1) mixed sex rat pups. Animals were
euthanized using pentobarbital injection followed by cervical
dislocation, according to Home Office guidelines. Cortical cell
suspensions were obtained as previously (60) described and
cytosine arabinoside (AraC, 2.4 μm final concentration) was
added to the growth medium at 1 days in vitro (DIV). Neurons
were transfected at 12 DIV with Lipofectamine 2000 (11668019,
Thermo Scientific) with either FLAG-tagged CHMP2BWildtype or
CHMP2BIntron5, described previously (61) and treated with either
or stavudine or lamivudine for 48 h (10 μm).
Statistical analysis
The statistical data were performed using GraphPad Prism (6.01).
Data are presented as mean values, from at least three indepen-
dent biological replicates, with error bars representing the stan-
dard error of mean. All details of the tests used were outlined
within each figure legend.
Supplementary Materials
Supplementary Materials are available at HMG online.
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